Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP493208.RAohmMWJfNIKN_kDZUpGos2Qzk2AgbiHrDZ7ONJZY-ZR4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP493208.RAohmMWJfNIKN_kDZUpGos2Qzk2AgbiHrDZ7ONJZY-ZR4130_assertion type Assertion NP493208.RAohmMWJfNIKN_kDZUpGos2Qzk2AgbiHrDZ7ONJZY-ZR4130_head.
- NP493208.RAohmMWJfNIKN_kDZUpGos2Qzk2AgbiHrDZ7ONJZY-ZR4130_assertion description "[Despite increasing use of 'targeted therapy,' interleukin-2 (IL-2) is unique, because this cytokine can induce long-term remissions in 5% to 7% of patients with metastatic melanoma and renal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP493208.RAohmMWJfNIKN_kDZUpGos2Qzk2AgbiHrDZ7ONJZY-ZR4130_provenance.
- NP493208.RAohmMWJfNIKN_kDZUpGos2Qzk2AgbiHrDZ7ONJZY-ZR4130_assertion evidence source_evidence_literature NP493208.RAohmMWJfNIKN_kDZUpGos2Qzk2AgbiHrDZ7ONJZY-ZR4130_provenance.
- NP493208.RAohmMWJfNIKN_kDZUpGos2Qzk2AgbiHrDZ7ONJZY-ZR4130_assertion SIO_000772 21577143 NP493208.RAohmMWJfNIKN_kDZUpGos2Qzk2AgbiHrDZ7ONJZY-ZR4130_provenance.
- NP493208.RAohmMWJfNIKN_kDZUpGos2Qzk2AgbiHrDZ7ONJZY-ZR4130_assertion wasDerivedFrom befree-20150227 NP493208.RAohmMWJfNIKN_kDZUpGos2Qzk2AgbiHrDZ7ONJZY-ZR4130_provenance.
- NP493208.RAohmMWJfNIKN_kDZUpGos2Qzk2AgbiHrDZ7ONJZY-ZR4130_assertion wasGeneratedBy ECO_0000203 NP493208.RAohmMWJfNIKN_kDZUpGos2Qzk2AgbiHrDZ7ONJZY-ZR4130_provenance.